The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
| Excerpt | Reference |
|---|
| "During the study, disease progression occurred in seven of the eight (88%) patients with a mutation at codon 215, compared with 7 of 18 (39%) patients assigned to the placebo group and 3 of the 12 (25%) patients receiving zidovudine treatment who did not develop a 215-mutant strain (p < 0." | ( Calderón, EJ; Larder, B; Leal, M; Lissen, E; Luque, F; Medrano, FJ; Rey, C; Sánchez-Quijano, A; Torres, Y, 1995) |
| "Efficacy end points included time to disease progression (TDP), time to treatment failure (TTF), survival, tumor response rates, and quality of life (QL) and relief of cancer-related symptoms." | ( Bigley, J; Budman, D; Hohneker, J; Hutchins, L; Jones, S; Laufman, L; Lembersky, B; O'Rourke, M; Vogel, C; Winer, E, 1995) |
| "With antiretroviral therapy, disease progression is not equivalent to drug failure, which is not equivalent to drug resistance." | ( Richman, DD, 1994) |
| "Benefit in terms of disease progression was seen mainly in participants not previously treated with AZT and overall." | ( , 1996) |
| "To compare disease progression and survival of patients with stage D1 adenocarcinoma after treatment with either early androgen ablation alone or combined with radical prostatectomy." | ( Lubos, W; Schmeller, N, 1997) |
| "The difference in survival and disease progression between the two groups was estimated allowing for treatment changes." | ( Babiker, AG; Darbyshire, JH; Walker, S; White, IR, 1997) |
| "Treatment was continued until disease progression or unacceptable toxicity." | ( Chu, L; Havlin, KA; Peterson, BL; Sutton, LM; Winer, EP, 1996) |
| "All had disease progression or relapse within 1 year of receiving platinum-containing first-line chemotherapy." | ( Alvarez, AM; Blajman, C; Breier, S; Cazap, E; Cóppola, FS; Ezcurdia, L; Fasce, H; Fein, L; Jovtis, SL; Lewi, D; Luchina, AM; Martínez, CA; Mickiewicz, E; Pasccón, G; Polera, J; Politi, PM; Rondinón, M; Rubio, G; Temperley, G; Triguboff, E; Uranga, G, 1997) |
| "This ability to decrease the risk of disease progression led to the recent approval of carvedilol for the treatment of chronic heart failure by the US Food and Drug Administration." | ( Packer, M, 1997) |
| "Children without disease progression on induction chemotherapy were offered consolidation with myeloablative chemotherapy that incorporated carboplatin, thiotepa, and etoposide followed by ABMR." | ( Allen, J; Bayer, L; Dunkel, IJ; Finlay, JL; Gardner, S; Garvin, J; Grovas, A; Halpern, S; Heller, G; Lindsley, K; Lyden, D; Mason, WP; Merchant, TE; O'Malley, B; Petriccione, MM; Puccetti, D; Rosenblum, M; Sands, S, 1998) |
| "Treatment then was suspended, but if disease progression was found, treatment was resumed using different drugs." | ( Altavilla, G; Brandes, AA; Carollo, C; Chierichetti, F; Ermani, M; Florentino, MV; Rigon, A; Turazzi, S; Zampieri, P, 1998) |
| "Rates of disease progression or death were 23% (11/47), 25% (13/53), and 12% (6/51) for the zidovudine plus nevirapine, zidovudine plus didanosine, and triple drug therapy groups, respectively (P=." | ( Conway, B; Cooper, D; Hall, D; Harris, M; Lange, JM; Montaner, JS; Myers, M; Reiss, P; Robinson, P; Smith, D; Vella, S; Wainberg, MA, 1998) |
| "The following were recorded: disease progression (CDC class), nutritional status (weight Z-score), CD4 lymphocyte count, drug treatment during the previous 12 months, presence of opportunistic infections, clinical evidence of acute pancreatitis (increased serum pancreatic enzymes associated with vomiting, abdominal distention, and intolerance when eating)." | ( Bastoni, K; Bavusotto, A; Boccia, MC; Canani, RB; Carroccio, A; Fontana, M; Guarino, A; Montalto, G; Spagnuolo, MI; Verghi, F; Zuin, G, 1998) |
| "At the time of disease progression compared to pretreatment, there was no significant change in expression of either receptor, irrespective of initial response." | ( Dowsett, M; Johnston, SR; Newby, JC; Smith, IE, 1997) |
| "With disease progression, there was a steady decline in the ability of betaCAA treatment to promote Th2-type cellular and humoral autoimmunity." | ( Kaufman, DL; Tian, J, 1998) |
| "Clinical features predictive of disease progression include initial lymphadenopathy (stage IIA) and lack of complete response to initial treatment." | ( Chow, S; Hoppe, RT; Kim, YH; Varghese, A, 1999) |
| "Therapy was continued until disease progression." | ( Heelan, R; Ilson, DH; Kelsen, DP; Martin, L; O'Reilly, EM; Saltz, LB, 1999) |
| "The median time to disease progression was worse for the patients treated with tamoxifen (P=0." | ( Agarwala, SS; Ferri, W; Gooding, W; Kirkwood, JM, 1999) |
| "As age is an important determinant of disease progression, it should be considered in recommending treatment." | ( Brettle, RP; Broers, B; Carré, N; Coutinho, RA; Goldberg, DJ; Hernández Aguado, I; Prins, M; Robertson, JR; van den Hoek, A; Zangerle, R, 1999) |
| "Both sexes experienced reductions in disease progression with lovastatin; there was no evidence of an overall sex x treatment interaction (P=0." | ( Applegate, WB; Byington, RP; Espeland, MA; Evans, GW; Furberg, CD; Hunninghake, DB; Probstfield, J, 1999) |
| "Time to treatment failure (disease progression, disease recurrence, or death) after autotransplantation." | ( Antman, KH; Armitage, JO; Bitran, JD; Fay, JW; Fields, KK; Freytes, CO; Gale, RP; Herzig, RH; Horowitz, MM; Kennedy, MJ; Klein, JP; Lazarus, HM; McCarthy, PL; Pecora, AL; Pelz, CJ; Reed, E; Rowlings, PA; Sobocinski, KA; Spitzer, G; Stadtmauer, EA; Vaughan, WP; Williams, SF; Wolff, SN, 1999) |
| "After disease progression, patients treated with bicalutamide were assigned to castration." | ( Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Conti, G; Cruciani, G; Dammino, S; Delliponti, U; Ditonno, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rubagotti, A; Spano, G, 1999) |
| "Measures of disease progression rates in Huntington's disease patients and asymptomatic mutation carriers will be of critical importance in future trials of experimental restorative treatments." | ( Andrews, TC; Brooks, DJ; Gunn, RN; Hodges, JR; Rosser, AE; Sahakian, B; Turjanski, N; Watkins, LH; Weeks, RA; Wood, NW, 1999) |
| "Median times to disease progression for the three treatment arms were as follows: 9." | ( Lorenz, M; Müller, HH, 2000) |
| "Treatment was continued until disease progression or toxicity." | ( Anderson, A; Cameron, DA; Howell, A; Leonard, RC; Ostrowski, J, 2000) |
| "Before disease progression, patients treated with TMZ were found to have an improvement in most of the preselected HRQOL domain scores compared with their baseline (pretreatment) scores." | ( Brada, M; Osoba, D; Prados, M; Yung, WK, 2000) |
| "Delaying disease progression by treatment with TMZ is beneficial to the HRQOL status of patients with recurrent GBM." | ( Brada, M; Osoba, D; Prados, M; Yung, WK, 2000) |
| "Patients actually treated at disease progression (34/70) survived shorter than those who had neither disease progression nor treatment (56 vs > 92 months; P = 0." | ( Ascari, E; Barbarano, L; Bergonzi, C; Brugnatelli, S; De Paoli, A; Delfini, C; Di Stasi, M; Giordano, M; Mora, O; Nicoletti, G; Piccinini, L; Riccardi, A; Rinaldi, E; Spanedda, R; Tinelli, C; Valentini, D, 2000) |
| "To compare HIV-disease progression according to changes of plasma HIV RNA observed in the year following initiation of a new antiretroviral treatment." | ( Chêne, G; Dabis, F; Jacqmin-Gadda, H; Mercié, P; Morlat, P; Neau, D; Thiébaut, R, 2000) |
| "More rapid disease progression was observed among infected children exposed during pregnancy or birth to Zdv if effective multidrug therapy was not initiated." | ( Abrams, EJ; Bulterys, M; Kuhn, L; Lambert, G; Nesheim, SR; Palumbo, P; Schoenbaum, EE; Vink, PE; Weedon, J, 2000) |
| "Treatment continued until disease progression, excess toxicity or patient refusal." | ( Barbounis, V; Demiri, M; Efremidis, AP; Koumakis, G; Pateras, H; Vassilomanolakis, M, 2000) |
| "To compare the rate of disease progression according to viral load and CD4 cell count in patients receiving or not receiving highly active antiretroviral therapy (HAART), defined as protease inhibitor-containing regimens." | ( Findhammer, S; Helm, EB; Miller, V; Phillips, AN; Rabenau, H; Rickerts, V; Rottmann, C; Sabin, CA; Staszewski, S; Weidmann, E, 2000) |
| "A decrease of the rate of radiographic disease progression with treatment in this group of patients was reflected by the decline in the slope of the radiographic score." | ( Fenner, H; Herborn, G; Rau, R; Zueger, S, 2000) |
| "Thus, a more rapid disease progression rate while receiving placebo treatment was predictive of a significantly stronger patient response to rivastigmine therapy." | ( Anand, R; Farlow, MR; Hake, A; Hartman, R; Messina, J; Veach, J, 2001) |
| "Rate of disease progression for patients with mild to moderate AD seems to predict response to rivastigmine treatment." | ( Anand, R; Farlow, MR; Hake, A; Hartman, R; Messina, J; Veach, J, 2001) |
| "It is mainly related to disease progression and levodopa treatment." | ( Giladi, N; Kandinov, B; Korczyn, AD; Orlov, Y; Paleacu, D; Shabtai, H; Simon, ES; Treves, TA, 2001) |
| "Chemotherapy was continued until disease progression or complete response occurred." | ( Gassel, HJ; Heinrich, S; Junginger, T; Köhne, CH; Lorenz, M; Mattes, E; Mueller, HH; Saeger, HD; Schramm, H; Staib-Sebler, E; Vetter, G, 2001) |
| "Radiographic disease progression with leflunomide and sulfasalazine treatment was assessed in rheumatoid arthritis patients in a double-blind trial that was placebo controlled for the first 6 months." | ( Kvien, TK; Larsen, A; Oed, C; Rau, R; Rosenburg, R; Rozman, B; Schattenkirchner, M; Scott, DL; Smolen, JS; Tikly, M; Westhovens, R, 2001) |
| "Responses to treatment and disease progression were determined by comparing scores with baseline scores." | ( Chainani-Wu, N; Lozada-Nur, F; Mayer, P; Silverman, S; Watson, JJ, 2001) |
| "The surrogate role of markers of disease progression (haemoglobin and prostate specific (PSA) antigen levels; number of bone scan-positive sites), symptomatic factors (analgesic intake; number of painful bone sites) and history of prior external radiotherapy, were analysed to determine whether any parameters had a predictive effect on the success of strontium-89 treatment." | ( Windsor, PM, 2001) |
| "Treatment continued until disease progression or unacceptable toxicity were encountered." | ( Ahern, R; Benson, C; Bridle, H; Eisen, T; Gore, ME; Mak, I; Pyle, L; Sapunar, F; Smalley, K; Stebbing, J, 2001) |
| "HAART resulted in decreased disease progression among persons with fewer than, but not more than, 200 x 10(6) CD4 lymphocytes/l prior to treatment." | ( Chaisson, RE; Moore, RD; Sterling, TR, 2001) |
| "Supplemental therapy was withheld until disease progression was documented." | ( Haik, BG; Merchant, TE; Moshfeghi, DM; Pratt, CB; Rodriguez-Galindo, C; Wilson, MW, 2001) |
| "To describe rates of disease progression to death and AIDS or death among patients starting triple-drug antiretroviral therapy, stratified by baseline CD4 cell count and HIV RNA levels." | ( Chan, KJ; Craib, KJ; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Wood, E; Yip, B, 2001) |
| "In our study, disease progression to death and AIDS or death was clustered among patients starting therapy with CD4 cell counts less than 200/microL." | ( Chan, KJ; Craib, KJ; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Wood, E; Yip, B, 2001) |
| "Patients continued treatment until disease progression, unacceptable toxicity, or death occurred." | ( Abbruzzese, JL; El-Naggar, AK; Ginsberg, LE; Glisson, BS; Herbst, RS; Hong, WK; Khuri, FR; Lawhorn, KN; Myers, JN; Pluda, JM; Roach, JS; Shin, DM; Steinhaus, GD; Teddy, S; Thall, PF; Tseng, JE; Wang, X; Zentgraf, RE, 2001) |
| "Patients with documented disease progression treated with chemotherapy and/or corticosteroids were followed between 1985 and 2000." | ( Ahmed, AR; Baltatzis, S; Foster, CS; Miserocchi, E; Roque, MR, 2002) |
| "All patients (100%) experienced disease progression on trastuzumab alone at or before the first 12 weeks of treatment." | ( Kelly, WK; Kenneson, K; Morris, MJ; Osman, I; Reuter, VE; Scher, HI; Slovin, SF; Verbel, D, 2002) |
| "Reductions in the risk of disease progression were seen across the entire patient population, irrespective of primary treatment or disease stage." | ( Carroll, K; Chodak, G; Delaere, KP; Gleason, D; Iversen, P; Klimberg, I; Kolvenbag, GJ; Lukkarinen, O; McLeod, DG; Montie, J; Persson, BE; See, WA; Tammela, TL; Tyrrell, C; Vaage, S; Wallace, DM; Wirth, MP, 2002) |
| "Treatment was administered weekly until disease progression or unacceptable toxicity." | ( Gennatas, K; Kosmas, C; Kouraklis, G; Margaris, E; Papastratis, G; Rokana, S; Skopelitis, E; Tsavaris, N; Vadiaka, M; Xila, V; Zografos, G, 2002) |
| "After disease progression, patients treated with B were assigned to castration." | ( Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Cortellini, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rigatti, P; Rubagotti, A; Usai, E, 2002) |
| "Although rapid disease progression had resolved transiently, after the start of high-dose chemotherapy, re-progression was apparently observed from day 14." | ( Hosoi, H; Iehara, T; Misawa, A; Sawada, T; Sugimoto, T; Tsuchiya, K, 2003) |
| "To evaluate frequencies of early disease progressions and recurrences in patients with familial vs sporadic ovarian cancers following primary paclitaxel/cis- or carboplatin chemotherapy." | ( Kruczek, A; Markowska, J; Skasko, E; Steffen, J; Wojciechowska-Lacka, A, 2003) |
| "The risk of rapid disease progression overwhelming the anti-cachectic palliative effect should be kept in mind when progestins are administered as a palliative treatment of cancer cachexia in patients with advanced "hormone-resistant" prostate cancer." | ( Fochessati, F; Panzini, I; Poggi, B; Ravaioli, A; Sartori, S; Tassinari, D, 2003) |
| "Here, we show that disease progression in SJL/J mice with EAE is improved after treatment with either a subtherapeutic dose of cyclosporine A (CsA) or NOX-100, a nitric oxide scavenger." | ( Chen, LS; Howard, RB; Jolivalt, CG; Lai, CS; Mizisin, AP, 2003) |
| "On subsequent disease progression, patients were retreated with 5-FU alone (5-FU group) or 5-FU plus mitomycin C (MMC group)." | ( Chau, I; Cunningham, D; Hill, M; Norman, AR; Ross, PJ; Yeoh, C, 2003) |
| "Treatment was continued until disease progression, excess toxicity, or patient refusal." | ( Barbounis, V; Demiri, M; Efremidis, AP; Koumakis, G; Missitzis, J; Vassilomanolakis, M, 2003) |
| "Data on the short-term risk of disease progression in HIV-1-infected children are needed to address the question of when to begin combination antiretroviral therapy." | ( Dunn, D, 2003) |
| "Treatment was given until disease progression or unacceptable toxicity." | ( Han, JY; Ju, SY; Kim, EA; Kim, HY; Lee, DH; Lee, JJ; Lee, JS; Shin, EH, 2003) |
| "The risk for death or disease progression was evaluated in unadjusted analyses and using a Cox proportional hazards model, adjusting for: study site, age, gender, race, route of HIV infection, previous AIDS-defining conditions, number of previous antiretroviral regiments, CD4 count, HIV-1 RNA, and treatment variables." | ( Becker, SL; Danehower, SC; Fusco, GP; Fusco, JS; Graham, NM; Hansen, NI; Justice, AC; Sherrill, BH; Stein, DS, 2004) |
| "Documented disease progression and confirmation of the absence of other treatment options were requested." | ( Baas, P; Haringhuizen, A; Vaessen, HF; van Tinteren, H; van Zandwijk, N, 2004) |
| "Patients with disease progression during the initial 8 weeks had the trastuzumab discontinued and were treated with weekly paclitaxel/carboplatin." | ( Broome, C; Burris, H; Greco, FA; Hainsworth, J; Houston, G; Jones, S; Thompson, D; White, M; Yardley, D, 2004) |
| "Treatment continued until disease progression, intolerable toxicity, or patient' s decision to discontinue." | ( Amin, B; Chen, YM; Gradishar, WJ; Hill, T; Lower, EE; Marcom, PK; Meza, LA; Samid, D, 2004) |
| "In cases of disease progression, the addition of irinotecan to cetuximab monotherapy was permitted." | ( Bets, D; Bleiberg, H; Chau, I; Cunningham, D; Harstrick, A; Humblet, Y; Khayat, D; Mueser, M; Santoro, A; Siena, S; Van Cutsem, E; Verslype, C, 2004) |
| "Irinotecan given until disease progression is an accepted standard treatment for advanced colorectal cancer (CRC) resistant to fluoropyrimidines." | ( Chau, I; Cunningham, D; Dickson, J; Hill, M; Lal, R; Middleton, G; Norman, AR; Oates, J; Ross, PJ; Topham, C, 2004) |
| "BDNF treatment slowed the disease progression maximally at a dose of 20 mg/kg, consistent to the previous evidence." | ( Ishiyama, T; Mitsumoto, H; Nakayama, C; Nishibe, H; Okada, R, 2004) |
| "To examine the effect of V64I on disease progression in patients receiving therapy, we determined CCR2 genotypes in the Women's Interagency HIV Study cohort." | ( Anastos, K; Burger, H; Cohen, M; Dupuis, M; Gange, SJ; Greenblatt, RM; Kovacs, A; Lu, M; Minkoff, H; Miotti, P; Philpott, S; Tarwater, PM; Weiser, B; Young, M, 2004) |
| "No therapy has been shown to halt disease progression or to prevent its onset." | ( Dundon, TA; Kenerson, H; Yeung, RS, 2005) |
| "Therapy was continued until disease progression or unacceptable toxicity." | ( Govindan, R; Green, MR; Herndon, JE; Kindler, HL; Kratzke, RA; Niehans, GA; Vollmer, R; Watson, D, 2005) |
| "The patient remained free from disease progression for a total of 15 months when she was treated for dehydration and a computed tomography (CT) scan showed new small bilateral pleural effusions and enlarging subcarinal, right hilar, and left infrahilar lymph nodes." | ( Langer, CJ; Somer, RA, 2005) |
| "None of the 9 patients had disease progression on therapy." | ( Bartels, U; Bouffet, E; Holm, S; Huang, A; Lafay-Cousin, L; Nicolin, G; Qaddoumi, I; Tabori, U, 2005) |
| "The response rate and the time to disease progression on first-line hormone therapy were not affected by serum HER-2/neu conversion." | ( Ali, SM; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, D; Hackl, W; Hamer, P; Harvey, HA; Lang, R; Leitzel, K; Lipton, A, 2005) |
| "No patient experienced disease progression during initial topotecan therapy." | ( Billups, CA; Davidoff, AM; Furman, WL; Hoffer, F; Houghton, PJ; Santana, VM; Stewart, CF, 2005) |
| "The median time to disease progression was 6 months, the median overall survival was 14 months, and the median time to treatment failure was 15 months." | ( Deckert, PM; Hütter, G; Keilholz, U; Schmittel, A; Siehl, JM; Szelényi, H; Thiel, E, 2005) |
| "Arm A included patients with disease progression <3 months and arm B included patients with disease progression > or =3 months after previous treatment." | ( Adjei, AA; Aubry, MC; Dy, GK; Jett, JR; Langdon, RM; Mandrekar, SJ; Miller, AA; Morton, RF; Schild, SE, 2005) |
| "A total of 23 patients with evidence of disease progression during or after first-line chemotherapy (epirubicin, etoposide, and dexamethasone) were included in this study." | ( Dolezal, J; Dolezel, M; Moravek, P; Odrazka, K; Petera, J; Prosvic, P; Simakova, E; Vaculikova, M; Vosmik, M; Zoul, Z, 2005) |
| "Patients were eligible if they had disease progression to prior chemotherapy (anthracycline-including or not) for early breast cancer or MBC." | ( Carlini, P; Carpino, A; Cianciulli, AM; Ciccarese, M; Cognetti, F; Fabi, A; Felici, A; Ferretti, G; Giannarelli, D; Lorusso, V; Mottolese, M; Papaldo, P; Salesi, N; Sperduti, I, 2006) |
| "Twenty-five patients with disease progression after receiving estrogen therapy received subsequent EMP-based chemotherapy." | ( Garcia, JA; Small, EJ; Weinberg, V, 2005) |
| "Six of 53 patients were alive and disease progression free at 6 months from the start of treatment (11." | ( Dutcher, JP; Friedland, DM; Leon, L; Manola, J; Roth, B; Wilding, G, 2005) |
| "The median time to disease progression in patients with multiple myeloma who receive initial therapy with Thal/Dex and who do not undergo ASCT is 18 months." | ( Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, S; Kyle, RA; Lacy, MQ; Lust, JA; Nowakowski, GS; Rajkumar, SV; Witzig, TE, 2005) |
| "Using models for disease progression and pharmacodynamic models for drug effects we have characterized the changes in UPDRS over time to determine the influence of the various drug treatments." | ( Chan, PL; Holford, NH; Kieburtz, K; Nutt, JG; Shoulson, I, 2006) |
| "Patients with documented disease progression during or after first-line treatment with CPT-11 and 5-FU/LV were enrolled." | ( Boukovinas, I; Christofillakis, C; Georgoulias, V; Potamianou, A; Syrigos, K; Tselepatiotis, E; Tsousis, S; Varthalitis, I; Ziras, N, 2006) |
| "The criterion for defining disease progression was time elapsed until doubling of baseline creatinine level and until dialysis therapy." | ( Amore, A; Andrulli, S; Cagnoli, L; Conti, G; Coppo, R; Gianoglio, B; Locatelli, F; Peruzzi, L, 2006) |
| "Treatment continued until disease progression or intolerable toxicity." | ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007) |
| "All patients had disease progression after anthracycline/taxane (A/T) therapy." | ( Aslanis, V; Bourbouloux, E; Campone, M; Ciruelos, E; Colin, C; Cortes-Funes, H; Delgado, FM; Fumoleau, P; Martin, M; Mendiola, C; Slabber, CF; Vorobiof, D, 2006) |
| "Altered disease progression, combined with the emergence of this particular cytokine pattern, indicates that short-term treatment with an anti-CD3 antibody induces a regulatory T-cell phenotype that restores self-tolerance in a mouse model of atherosclerosis." | ( Burger, F; Chatenoud, L; Dean, Y; Elson, G; Kosco-Vilbois, M; Mach, F; Pelli, G; Steffens, S, 2006) |
| "Patients received Fulvestrant after disease progression (PD) on a previous endocrine treatment or as maintenance treatment after chemotherapy." | ( Adamoli, L; Ascione, G; Catania, C; De Pas, T; Franceschelli, L; Goldhirsch, A; Magni, E; Medici, M; Nolè, F; Sanna, G; Torrisi, R; Verri, E, 2007) |
| "Six patients had renal disease progression; most (four of six) were older than 40 yr and had significant proteinuria at baseline and evidence of sclerotic glomeruli pretreatment." | ( Abichandani, R; Banikazemi, M; Bushinsky, DA; Charrow, J; Desnick, RJ; Germain, DP; Guffon, N; Lee, P; Loew, T; Vedder, AC; Waldek, S; Wilcox, WR, 2007) |
| "Among patients with treatment delay, disease progression was registered in 30 (63%) patients." | ( Chi, CW; Chiang, JH; Huang, YH; Huo, TI; Lee, PC; Lee, SD; Wu, JC, 2007) |
| "Time-to-disease progression (primary therapy for prostate cancer or pathologic progression), positive cores, change in Gleason score, and QOL assessments will be compared between groups." | ( Cookson, MS; Evans, A; Finelli, A; Fleshner, N; Gomella, LG; Lucia, MS; Rittmaster, R; Somerville, MC; Taneja, SS; Wolford, E, 2007) |
| "Different stages of disease progression are associated with varying prognoses and potential responses to therapy, which provide a strong rationale for early intervention." | ( Wanner, C, 2007) |
| "Patients had experienced disease progression after one prior cisplatin- or carboplatin-based chemotherapy regimen." | ( Bonomi, P; Breton, JL; Delbaldo, C; Edelman, M; Edelman, MJ; Lara, PN; Le Chevalier, T; Lebwohl, D; McHenry, B; Peck, R; Sandler, AB; Socinski, MA; Vansteenkiste, J, 2007) |
| "MBC patients, who had experienced disease progression while receiving or within 4 months of taxane therapy (6 months if adjuvant taxane only), and who had a taxane as their last regimen, received ixabepilone (1- or 3-hour infusion of 50 mg/m(2) or 3-hour infusion of 40 mg/m(2) every 3 weeks)." | ( Baselga, J; Bunnell, CA; Burris, HA; Conté, P; Fornier, M; Fumoleau, P; Guarneri, V; Klimovsky, J; Lebwohl, D; Lluch, A; Martin, M; Poulart, V; Rivera, E; Tabernero, J; Thomas, E; Vahdat, LT; Viens, P, 2007) |
| "Six patients experienced early disease progression, and four patients died while on treatment." | ( Daniels, S; McTiernan, A; Roylance, R; Seddon, B; Sykes, K; Whelan, J, 2007) |
| "Early treatment may prevent disease progression." | ( Gordon, CM; Hassan, A, 2007) |
| "To review the clinical features, disease progression, and effects of treatment on idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis (IRVAN)." | ( Chang, TS; Equi, RA; Hay, D; Jampol, LM; Mieler, W; Samuel, MA; Yannuzzi, LA, 2007) |
| "All patients died from neoplastic disease progression despite further chemotherapy at 6, 17 and 31 months following the diagnosis of NRH." | ( Canon, JL; Ceratti, A; Gigot, JF; Horsmans, Y; Hubert, C; Humblet, Y; Machiels, JP; Rahier, J; Sempoux, C, 2007) |
| "Treatment lasted until disease progression, unacceptable toxicity, patient refusal or treatment delay for >2 weeks." | ( Bokemeyer, C; Buchheidt, D; Hartmann, JT; Hofheinz, RD; Izquierdo, MA; Keilholz, U; Millan, S; Peschel, C; Schmittel, A; Schneller, F, 2008) |
| "An interim analysis of time to disease progression (TTP), the primary endpoint, was conducted after 249 TTP events in this study that randomized 324 patients to liposomal doxorubicin plus bortezomib treatment and 322 patients to bortezomib monotherapy." | ( Dagher, R; Farrell, AT; He, K; Justice, R; Ning, YM; Pazdur, R; Sridhara, R, 2007) |
| "Reduced disease progression in ABS-75-treated mice was associated with reduced axonal loss and demyelination in the spinal cord." | ( Bar-Shir, A; Basso, AS; Costa-Pinto, FA; Engel, Y; Frenkel, D; Gozin, M; Monsonego, A; Petrovic-Stojkovic, S; Puckett, L; Quintana, FJ; Weiner, HL, 2008) |
| "Treatment was continued until disease progression, unacceptable toxicity, or patient refusal." | ( Artru, P; Asnacios, A; Fartoux, L; Hebbar, M; Louafi S, S; Mansoubakht, T; Poynard, T; Romano, O; Rosmorduc, O; Taieb, J; Tesmoingt, C, 2008) |
| "of sorafenib administered orally until disease progression or unacceptable toxicity." | ( Bajetta, E; Catena, L; Gevorgyan, A; Guadalupi, V; Mancin, M; Martinetti, A; Platania, M; Procopio, G; Pusceddu, S; Verzoni, E, 2007) |
| "COX-2 expression correlates with disease progression on endocrine treatment." | ( Crotty, TB; Dillon, MF; Hill, AD; Kelly, G; McDermott, E; McIlroy, M; Redmond, AM; Stafford, AT; Young, LS, 2008) |
| "For monitoring of disease progression and the effects of treatment programmes the Sollerman test is most suitable." | ( Beelen, A; de Visser, M; Nollet, F; van Schaik, IN; Videler, AJ, 2008) |
| "Treatment was continued until disease progression, unacceptable toxicity, non-compliance or consent withdrawal." | ( Ashraf, U; Chadha, MK; Escott, P; Lawrence, D; Levine, E; Payne, V; Silliman, C; Tian, L; Trump, DL, 2008) |
| "Patients were treated until evidence of disease progression or unacceptable toxicity." | ( Armstrong, AJ; Creel, P; George, DJ; Gockerman, JP; Haley, S; Hurwitz, H; Jaffe, TA; Moore, C; Petros, W; Sleep, D; Turnbull, J; Yenser, S, 2008) |
| "Fifty-four of the 73 patients with disease progression received third-line chemotherapy." | ( Ando, M; Fujiwara, Y; Kamura, T; Kasamatsu, T; Katsumata, N; Kouno, T; Matsumoto, K; Nishio, S; Shimizu, C; Tanabe, H; Yonemori, K, 2009) |
| "After disease progression despite the administration of CAV in clinically appropriate patients, alpha-interferon (alpha-IFN) (9 patients) was administered." | ( Chamberlain, MC; Glantz, MJ, 2008) |
| "Our findings of rapid disease progression among perinatally infected HIV positive children underline the importance of early diagnosis and treatment." | ( Devi, NP; Ramesh, K; Rathinam, SN; Shenbagavalli, R; Swaminathan, S, 2009) |
| "Four factors emerged as predictors of disease progression: molecular response, cytogenetic response, disease phase and disease duration prior to imatinib treatment, but only the latter three remained significant after multivariate analysis." | ( Cai, Z; Cao, W; Huang, H; Lai, X; Lin, M; Liu, L; Luo, Y; Shi, J; Tan, Y; Wang, Y; Wu, G; Xie, W; Ye, X; Zhao, Y, 2009) |
| "We describe the demographic features, disease progression, antiretroviral therapy (ART), and resistance in young people aged 10 years or more living in the United Kingdom and Ireland reported to the National Study of HIV in Pregnancy and Childhood (NSHPC) with prospective annual follow-up in the Collaborative HIV Paediatric Study (CHIPS) between 1996 and September 2007." | ( Butler, K; Dunn, D; Foster, C; Gibb, D; Judd, A; Lyall, H; Sharland, M; Shingadia, D; Tookey, P; Tudor-Williams, G, 2009) |
| "Differences in disease progression occurred from the third year on ART, whereas higher rates of switch to second-line treatment occurred in LCM from the second year." | ( Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E, 2010) |
| "So far there is no therapy that halts disease progression." | ( Serra, AL; Wüthrich, RP, 2009) |
| "Treatment was discontinued at disease progression and/or serious toxicity." | ( Ardavanis, A; Doufexis, D; Karagiannis, A; Kountourakis, P; Rigatos, G; Tzovaras, AA, 2009) |
| "We compared the incidence of HIV disease progression among antiretroviral therapy-naive women with and without exposure to hormonal contraception at 13 sites in Africa and Asia." | ( Abrams, EJ; Carter, RJ; El-Sadr, W; Giganti, M; Stringer, EM; Stringer, JS, 2009) |
| "Effect of acyclovir on HIV-1 disease progression was defined by a primary composite endpoint of first occurrence of CD4 cell counts of fewer than 200 cells per microL, antiretroviral therapy initiation, or non-trauma related death." | ( Allen, S; Baeten, JM; Barnes, L; Bukusi, EA; Celum, C; Coetzee, D; Cohen, CR; Corey, L; de Bruyn, G; Delany, S; Essex, M; Farquhar, C; Fife, KH; Gray, GE; Hughes, JP; Inambao, M; Kanweka, W; Kapiga, S; Karita, E; Katabira, E; Kayitenkore, K; Kiarie, J; Kidoguchi, L; Lingappa, JR; Magaret, AS; Makhema, J; Manongi, R; McIntyre, JA; Mugo, N; Mujugira, A; Rees, H; Ridzon, R; Ronald, A; Stewart, GJ; Thomas, KK; Vwalika, B; Wald, A; Wang, RS; Were, E, 2010) |
| "During disease progression, and after androgen ablation therapy, the remaining operational pathways are upregulated to compensate for the lost growth signal, finally resulting in androgen-independent prostate cancer." | ( Wertz, K, 2009) |
| "Patients continued treatment until disease progression, unacceptable toxicity, or withdrawal of consent." | ( Akaza, H; Fujimoto, H; Naito, S; Tsukamoto, T; Usami, M, 2010) |
| "Treatment was repeated until disease progression, unacceptable toxicity, or up to 6 cycles." | ( Cho, EK; Jung, SH; Kim, YS; Kyung, SY; Lee, JH; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB; Sym, SJ, 2011) |
| "Patients remained on therapy until disease progression." | ( Jagannath, S; Mazumder, A; Vesole, DH, 2010) |
| "The antibody treatment also prevented disease progression in arthritic mice, although without leading to remission." | ( Agua-Doce, A; Duarte, J; Fonseca, JE; Graca, L; Oliveira, VG, 2010) |
| "Allopurinol treatment slowed down renal disease progression independently of age, gender, diabetes, C-reactive protein, albuminuria, and renin-angiotensin system blockers use." | ( Ampuero, J; Arroyo, D; de Vinuesa, SG; Goicoechea, M; Luño, J; Rincón, A; Ruiz-Caro, C; Verdalles, U, 2010) |
| "Following relapse or disease progression, PLD/oxaliplatin chemotherapy was administered at 30 to 35 and 70 mg/m(2), respectively, over 2 day, every 4 weeks." | ( Borgato, L; Donach, ME; Furini, L; Lombardi, G; Nicoletto, MO; Palma, MD; Zustovich, F, 2011) |
| "Treatment continued until disease progression or discontinuation." | ( Cardoso, F; Chang, J; Fukase, K; Ianuli, C; Kahan, Z; Lindemann, JP; Macpherson, MP; Mauriac, L; Neven, P; Panasci, L; Papai, Z; Pritchard, KI; Rolski, J, 2010) |
| "This mechanism stimulates disease progression through reactivation of androgen receptor signaling in patients who have previously undergone castration therapy." | ( Hara, T; Kusaka, M; Yamaoka, M, 2010) |
| "Treatment continued until disease progression or treatment intolerance occurred." | ( Fukasawa, S; Ichikawa, T; Imamura, Y; Komaru, A; Maruoka, M; Naya, Y; Nihei, N; Sazuka, T; Suyama, T; Ueda, T, 2010) |
| "Patients who showed disease progression during the study period showed significantly higher CTX levels at baseline and after 18 months of ZA treatment than patients who did not progress (p = 0." | ( López-Carrizosa, MC; Pérez, AR; Samper-Ots, PM, 2010) |
| "Patients were treated until disease progression or unacceptable toxicity." | ( Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M, 2010) |
| "Treatment continued until disease progression." | ( Gill, JF; Hentschel, P; Higby, DJ; Khan, MQ; Leichman, CG; Madajewicz, S; Malik, SK; Nicol, SJ; Ritch, PS; Waterhouse, DM; Zhao, L, 2012) |
| "Thymulin activity is predictive of HIV disease progression and is depressed in cocaine users independent of antiretroviral treatment (ART) and HIV viral load." | ( Baum, MK; Campa, A; Huffman, F; Newman, F; Rafie, C; Smith, S, 2011) |
| "Two patients showed disease progression, and one of them died at 4 months after beginning of treatment." | ( Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R, 2011) |
| "Continued lenalidomide treatment until disease progression after achievement of ≥PR is associated with a significant survival advantage when controlling for patient characteristics." | ( Bravo, ML; Dimopoulos, MA; Harousseau, JL; Knight, RD; Olesnyckyj, M; Rajkumar, SV; San-Miguel, JF; Siegel, D; Stadtmauer, EA; Weber, DM; Zeldis, JB, 2011) |
| "Chemotherapy was administered until disease progression or unacceptable toxicity." | ( Barbanti, G; Bargagli, G; Chiriacò, G; Conca, R; De Rubertis, G; Fiaschi, AI; Francini, E; Francini, G; Manganelli, A; Pascucci, A; Petrioli, R; Ponchietti, R, 2011) |
| "Our findings suggest that liver disease progression observed in ART-treated co-infected patients is partly due to the consequences of treatment interruptions." | ( Klein, MB; Moodie, EE; Saeed, S; Thorpe, J, 2011) |
| "Factors associated with disease progression were pre-treatment PSADT (≥6 vs." | ( Antonarakis, ES; Carducci, MA; Denmeade, S; Eisenberger, MA; Huang, P; Keizman, D; Kim, JJ; Sinibaldi, V; Walczak, J, 2011) |
| "Importantly, HIV disease progression despite elite control of HIV replication or virologic success on antiretroviral treatment is associated with persistent damage to the lymphopoietic system or exhaustion of lymphopoiesis." | ( Ait-Mohand, H; Appay, V; Autran, B; Bailey, M; Boufassa, F; Carcelain, G; Costagliola, D; Deeks, SG; Duvivier, C; Fastenackels, S; Gorochov, G; Guihot, A; Hunt, PW; Iguertsira, M; Katlama, C; Kelleher, AD; Lambotte, O; Larsen, M; Meyer, L; Pauchard, M; Sauce, D; Schneider, L; Simon, A; Zaunders, J, 2011) |
| "Treatment continued until disease progression, intolerable toxicity, or consent withdrawal." | ( Chen, JS; Chen, PT; Chen, YY; Hsu, HC; Huang, JS; Lin, YC; Shen, WC; Wang, HM; Yeh, KY, 2012) |
| "Corticosteroid treatment slows disease progression and is the standard of care for Duchenne muscular dystrophy (DMD)." | ( Connolly, AM; Escolar, DM; Florence, J; Gorni, K; Henricson, E; Hu, F; Martin, GR; Mayhew, J; Nie, L; Pasquali, L; Pestronk, A; Rocha, CT; Spurney, CF, 2011) |
| "Patients in the control group with disease progression (>25% increase in mRSS or decrease of >10% in forced vital capacity) despite treatment with cyclophosphamide could switch to HSCT 12 months after enrolment." | ( Barr, W; Boyce, K; Burt, RK; Carr, J; Craig, R; Dill, K; Gheorghiade, M; Grant, T; Hirano, I; Jain, S; Jovanovic, B; Marshall, K; Milanetti, F; Morgan, A; Ruderman, E; Schroeder, J; Shah, SJ, 2011) |
| "Eight of nine controls had disease progression (without interval improvement) compared with no patients treated by HSCT (p=0·0001), and seven patients switched to HSCT." | ( Barr, W; Boyce, K; Burt, RK; Carr, J; Craig, R; Dill, K; Gheorghiade, M; Grant, T; Hirano, I; Jain, S; Jovanovic, B; Marshall, K; Milanetti, F; Morgan, A; Ruderman, E; Schroeder, J; Shah, SJ, 2011) |
| "Treatment was continued until disease progression, unacceptable toxicity, withdrawal of consent, or death." | ( Filipiak, KJ; Langiewicz, P; Nurzyński, P; Opolski, G; Szczylik, C; Szmit, S; Zaborowska, M; Złnierek, J, 2012) |
| "Secondary efficacy variables were disease progression, analgesia use, performance status and tolerability of therapy." | ( Cookson, MS; Gittelman, MC; Shore, N, 2012) |
| "To determine the treatment response and disease progression in strictly selected patients with myelodysplastic syndrome undergoing immunosuppressive therapy (IST), patients were required to have an international prognostic scoring system [corrected] (IPSS) score ≤ 1." | ( Li, X; Lingyun, W; Luxi, S; Qi, Z; Qiusheng, C; Xiao, L, 2012) |
| "At the time of disease progression, post-treatment samples were additionally collected from 8 clinical responders." | ( Aprelikova, O; Choi, IJ; Green, JE; Kim, CH; Kim, HK; Kim, J; Lee, ET; Munroe, DJ; Rettig, RL, 2011) |
| "Patients who did not experience disease progression after induction therapy continued bevacizumab therapy until disease progression or unacceptable toxicity." | ( Crinò, L; Felip, E; Franke, F; Gorbunova, V; Groen, H; Jiang, GL; Laskin, J; Reck, M; Schneider, CP, 2012) |
| "DHEA treatment did not alter disease progression or survival in SOD1-G93A rats." | ( Hayes-Punzo, A; McHugh, J; Meyer, M; Mulcrone, P; Suzuki, M; Svendsen, CN, 2012) |
| "No significant difference in HIV disease progression existed between participants in the treatment group and those in the placebo group who had baseline HIV viral loads of less than 50,000 copies per mL (0·90, 0·54-1·5; p=0·688)." | ( Boaz, I; Gray, RH; Kiwanuka, N; Makumbi, F; Mondo, G; Newell, K; Quinn, TC; Reynolds, SJ; Serwadda, D; Ssebbowa, P; Wawer, MJ, 2012) |
| "The predictors of disease progression included residual retroperitoneal nodal size after chemotherapy (P = ." | ( Bosl, GJ; Carver, BS; Feldman, DR; Masterson, TA; Motzer, RJ; Shayegan, B; Sheinfeld, J, 2012) |
| "Those at risk for liver disease progression are usually treated with a combination of interferon (IFN) and ribavirin (RBV), which is not highly effective; it has low rates of sustained virologic response (SVR), especially for coinfected patients with HCV genotype 1 and those of African descent." | ( Naggie, S; Sulkowski, MS, 2012) |
| "Patients with MBC who had disease progression after initial chemotherapy with anthracyclines (n = 29; 100 %) and taxanes (n = 11; 37." | ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012) |
| "Pre-treatment disease progression defined as the development of any new site of disease on PET/CT and change in TNM stage (AJCC 7th ed." | ( Kong, FM; Mahasittiwat, P; Quint, LE; Wang, J; Wong, KK, 2012) |
| "Pre-treatment disease progression occurred in 20." | ( Kong, FM; Mahasittiwat, P; Quint, LE; Wang, J; Wong, KK, 2012) |
| "The model is able to track disease progression and the response to treatment." | ( Chase, JG; Chiew, YS; Desaive, T; Janssen, N; Lambermont, B; Moeller, K; Schranz, C; Shaw, GM, 2012) |
| "Continuous therapy from relapse to disease progression may be able to maintain suppression of residual disease, thereby extending overall survival." | ( Ludwig, H; Sonneveld, P, 2012) |
| "To identify early determinants of HIV-1 disease progression, which could potentially enable individualized patient treatment, and provide correlates of progression applicable as reference phenotypes to evaluate breakthrough infections in vaccine development." | ( Carvalho, KI; Costa, PR; Giret, MT; Kallás, EG; Mahnke, YD; Nason, MC; Roederer, M; Sauer, MM; Song, K, 2013) |
| "Chemotherapy was stopped because of disease progression." | ( Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M, 2012) |
| "The mice showed more rapid disease progression when given cAMP-increasing agents (prostaglandin E2 analog and theophylline), both with and without DNR chemotherapy." | ( Bruserud, O; Døskeland, SO; Gausdal, G; Gjertsen, BT; Havemann, U; Herfindal, L; Kleppe, R; Lanotte, M; McCormack, E; Nguyen, E; Pendino, F; Rouhee, N; Schwede, F; Ségal-Bendirdjian, E; Skavland, J; Wergeland, A, 2013) |
| "Among the 96 patients with disease progression, 52% and 48% had Child-Pugh class A and class B/C disease, respectively, thereby substantially limiting the latter group's eligibility for systemic therapy and/or clinical trials." | ( Atassi, R; Ganger, D; Gupta, R; Kulik, L; Lewandowski, RJ; Memon, K; Miller, FH; Mulcahy, MF; Ryu, RK; Salem, R; Vouche, M, 2013) |
| "Only two patients have demonstrated disease progression during neoadjuvant therapy." | ( Bauer, S; Bonvalot, S; Bylina, E; Casali, PG; Cats, A; de Wilt, JH; Fiore, M; Fumagalli, E; Gronchi, A; Hohenberger, P; Hoiczyk, M; Kerst, JM; Le Cesne, A; Nguyen, BP; Nyckowski, P; Rutkowski, P; Schöffski, P; Sleijfer, S; Stoeckle, E; Tielen, R; Treckmann, J; van Coevorden, F; van der Graaf, W; Verhoef, C, 2013) |
| "Shorter disease progression and neuralgia and PCS etiologies are favorable factors for pregabalin treatment response." | ( Blanco Tarrio, E; Gálvez Mateos, R; López Gómez, V; Pérez Páramo, M; Zamorano Bayarri, E, 2013) |
| "Preantiretroviral therapy disease progression was measured by three time-to-event endpoints: CD4 cell count 350 cells/μl or less, viral load measurement at least 1 × 10 copies/ml, and clinical AIDS." | ( Allen, SA; Amornkul, PN; Anzala, O; Bekker, LG; Cormier, E; Fast, PE; Gilmour, J; Kamali, A; Karita, E; Kilembe, W; Lakhi, S; Latka, MH; Price, MA; Rida, WN; Sanders, EJ, 2013) |
| "We used population-level data on disease progression and antiretroviral treatment utilization from the BC HIV Drug Treatment Program." | ( Hogg, RS; Lima, VD; Min, J; Montaner, JS; Nosyk, B; Yip, B, 2013) |
| "Treatment continued until disease progression, intolerable toxic effects, or withdrawal of consent." | ( Feng, J; Geater, SL; Hou, M; Hu, CP; Huang, Y; Kim, M; Lee, KY; Li, W; Lu, S; Massey, D; Shi, JH; Shi, Y; Wu, YL; Xu, CR; Zhou, C, 2014) |
| "Relapse or disease progression after PBSCT was a frequent cause of death, but no therapy-related mortality associated with PBSCT was observed." | ( Hatta, Y; Hirabayashi, Y; Hojo, A; Horikoshi, A; Iriyama, N; Kiso, S; Kobayashi, S; Kobayashi, Y; Kodaira, H; Kura, Y; Kurita, D; Kusuda, M; Miura, K; Nakagawa, M; Sawada, U; Sugitani, M; Takahashi, H; Takei, M; Takeuchi, J; Uchino, Y; Yagi, M, 2014) |
| "Treatments received after disease progression were also assessed." | ( Azer, MW; Haydu, LE; Kefford, RF; Long, GV; Menzies, AM, 2014) |
| "There is no dominant site or pattern of disease progression in patients with brain metastases treated with dabrafenib." | ( Azer, MW; Haydu, LE; Kefford, RF; Long, GV; Menzies, AM, 2014) |
| "To determine whether SSRIs impact disease progression, fluoxetine (Prozac, 5 or 10 mg/kg) was administered to mutant superoxide dismutase 1 (SOD1) mice during one of three age ranges: neonatal [postnatal day (P)5-11], adult presymptomatic (P30 to end stage), and adult symptomatic (P70 to end stage)." | ( Heckman, CJ; Kajtaz, E; Kocevar, EJ; Koschnitzky, JE; Lukas, TJ; Mayers, WF; Quinlan, KA; Siddique, T, 2014) |
| "Both events were most likely related to disease progression rather than treatment; nonetheless, we conservatively classified the death as a dose limiting toxicity." | ( Andrews, DW; Bar-Ad, V; Berger, AC; Choy, H; Dicker, AP; Evans, JJ; Farrell, CJ; Judy, KD; Lawrence, YR; Moshel, Y; Shi, W; Werner-Wasik, M, 2014) |
| "The hazard ratio (HR) for disease progression was lower for both monotherapy with azathioprine (HR: 0." | ( Andrade, P; Camila-Dias, C; Coelho, R; Lopes, S; Macedo, G; Magro, F; Rodrigues-Pinto, E; Santos-Antunes, J, 2014) |
| "Metabolic acidosis is a cause of renal disease progression, and alkali therapy ameliorates its progression." | ( Han, JS; Heo, NJ; Kim, S; Lee, J; Lee, JW, 2014) |
| "The median time to disease progression from the first treatment with platinum drug was 3." | ( Brace, G; Bushati, T; Cakani, B; Kaloshi, G; Petrela, M; Roci, E; Rroji, A, 2014) |
| "The primary endpoint was time to disease progression, analysed by intention to treat." | ( Ashcroft, AJ; Bird, JM; Brown, JM; Cairns, DA; Cavenagh, J; Cavet, J; Chalmers, A; Cook, G; Drayson, MT; Fletcher, M; Hunter, H; Morris, TC; O'Connor, S; Parrish, C; Snowden, JA; Williams, C; Yong, K, 2014) |
| "Treatment continued until disease progression, unacceptable toxicity, or patient choice." | ( Abbas, H; Blazeby, JM; Chatterjee, A; Dahle-Smith, A; Davoudianfar, M; Dutton, SJ; Falk, S; Ferry, DR; Fyfe, DW; Gamble, T; Garcia-Alonso, A; Harrison, M; Hubner, RA; Jankowski, J; Julier, P; Kerr, R; Mansoor, W; Peachey, L; Pearson, SR; Petty, RD; Thompson, J, 2014) |
| "After 4 cycles, patients without disease progression received single-agent maintenance treatment with pemetrexed or oral vinorelbine." | ( Almodovar, T; Amoroso, D; Bennouna, J; Caux, NR; Ciuffreda, L; Cobo, M; Dansin, E; Favaretto, A; Gervais, R; Havel, L; Jassem, J; Kollmeier, J; Krzakowski, M; Melotti, B; Nicolini, M; Ramlau, R; Riggi, M; Serke, M; Szczesna, A; Tan, EH; Vaissière, N, 2014) |
| "Anti-Tat immunity may help delay HIV disease progression, thus, targeting Tat may offer a novel therapeutic intervention to postpone antiretroviral treatment or to increase its efficacy." | ( Angarano, G; Arancio, A; Bellino, S; Bonora, S; Cafaro, A; Di Perri, G; Di Pietro, M; Ensoli, B; Ensoli, F; Focà, E; Francavilla, V; Galli, M; Gori, A; Ladisa, N; Latini, A; Lazzarin, A; Longo, O; Mazzotta, F; Mercurio, VS; Monini, P; Mussini, C; Nozza, S; Palamara, G; Paniccia, G; Picconi, O; Sgadari, C; Sighinolfi, L; Tambussi, G; Torti, C; Tripiciano, A, 2014) |
| "In our patient, disease progression after second line targeted therapy and the absence of alternative treatment options for spontaneous rupture and hemoperitoneum prompted us to treat the patient aggressively." | ( Chung, KM; Lai, EC; Lau, SH; Lau, WY, 2015) |
| "Median OS on enzalutamide following disease progression on taxane-based chemotherapy and abiraterone was modest, but patients who experience a PSA decline >30% or 50%, respectively, with enzalutamide in this setting had longer survival." | ( Boegemann, M; Brasso, K; de Bono, J; Lorente, D; Merseburger, AS; Retz, M; Schmid, SC; Schrader, AJ; Thomsen, FB; von Klot, CA, 2015) |
| "Hence, monitoring of disease progression and response to therapy is suboptimal." | ( Friedman, A; Hao, W; Rovin, BH, 2014) |
| "The treatment outcome, risk factors for disease progression, and overall survival were retrospectively analyzed." | ( Ahn, JM; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Lim, HY; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC, 2015) |
| "Four patients had a disease progression date more than 6 months after the start of veliparib-topotecan therapy." | ( Bender, DP; Carter, JS; Dawson, D; Deng, W; Gray, HJ; Guaglianone, PP; Kunos, C; Lea, JS; Moore, KN; Zanotti, KM, 2015) |
| "Our observation of accelerated disease progression within some patients after stopping vemurafenib treatment has fostered the idea of treatment beyond progression (BRAFi TBP)." | ( Blank, CU; Geukes Foppen, MH; Haanen, JB; Scholtens, A; van Thienen, JV; van Tinteren, H, 2015) |
| "Among 31 patients who experienced disease progression following ibrutinib and underwent salvage therapy, the overall and complete response rates were 32% and 19%, respectively." | ( Champlin, RE; Cheah, CY; Chihara, D; Fowler, NH; Hagemeister, FB; Romaguera, JE; Seymour, JF; Wang, ML, 2015) |
| "Treatments and risk profiles determined disease progression." | ( Schwendicke, F; Stolpe, M; Tu, YK, 2015) |
| "Treatment was stopped for documented disease progression, unacceptable toxicity, or patient refusal." | ( Bernardo, A; Ferzi, A; Gambaro, A; Palumbo, R; Piazza, E; Pozzi, E; Sottotetti, F; Spinapolice, EG; Tagliaferri, B; Teragni, C; Trifirò, G, 2015) |
| "The Cardiff Model was used to simulate disease progression and estimate the long-term effect of treatments on patients." | ( Deng, J; Dong, H; Gu, S; Mu, Y; Shi, L, 2015) |
| "Time to disease progression was analyzed with Cox models adjusting for patient age, race, baseline prostate specific antigen, number of sampled and involved cores, tumor length and treatment." | ( Fleshner, NE; Freedland, SJ; Moreira, DM, 2015) |
| "Rapid disease progression associated with increased tumor proliferation has been observed during withdrawal of anti-angiogenic therapy." | ( Bruce, JY; Carmichael, LL; Eickhoff, JC; Heideman, JL; Jeraj, R; Kolesar, JM; Liu, G; Perlman, SB; Scully, PC, 2015) |
| "Early disease progression during second-line chemotherapy was significantly more frequently observed in patients with CC genotype of STMN1 in contrast to patients with presence of T allele (median PFS: 2 and 4 months; p = 0." | ( Bartoń, S; Biernacka, B; Krawczyk, P; Małecka-Massalska, T; Milanowski, J; Mlak, R; Powrózek, T, 2016) |
| "CsA stabilized disease progression on HRCT in the early treatment group (p = 0." | ( Go, DJ; Kang, EH; Kwon, HM; Lee, EB; Lee, YJ; Park, JK; Song, YW, 2016) |
| "Yet no therapy is proven to halt disease progression or to prevent the development of epilepsy." | ( Akula, KK; Boison, D; Coffman, SQ; Lusardi, TA; Masino, SA; Ruskin, DN, 2015) |
| "We evaluated disease progression and the effect of macitentan in treatment-naïve incident and prevalent cohorts." | ( Channick, RN; Delcroix, M; Galiè, N; Ghofrani, HA; Jansa, P; Le Brun, FO; Mehta, S; Perchenet, L; Pulido, T; Rubin, LJ; Sastry, BK; Simonneau, G; Sitbon, O; Souza, R; Torbicki, A, 2015) |
| "Moreover, the interruption of the disease progression after the antibiotic therapy is difficult to ignore without claiming that this association is at least suggestive." | ( di Meo, N; Nan, K; Pinzani, C; Stinco, G; Trevisan, G, 2015) |
| "After disease progression post-BV, the most common treatment strategies were investigational agents (n = 30), gemcitabine (n = 15) and bendamustine (n = 12)." | ( Anderlini, P; Cheah, CY; Chihara, D; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; Horowitz, S; Nastoupil, LJ; Neelapu, SS; Nieto, Y; Oki, Y; Rodriguez, MA; Romaguera, JE; Samaniego, F; Sevin, A; Turturro, F; Wang, M; Westin, JR; Zhou, S, 2016) |
| "During treatment, disease progression (PD) was diagnosed in 27 of 36 patients." | ( Bott, A; Buyl, R; Chevolet, I; Jacobs, B; Jansen, Y; Maertens, G; Meersseman, G; Neyns, B; Schreuer, M; Seremet, T; Van Den Herrewegen, S; Wilgenhof, S, 2016) |
| "It enables repetitive monitoring of disease progression and measurement of quantitative biomarkers that report on disease progression and therapy efficacy in the same animal, thereby reducing manifold the number of animals needed for in vivo studies whilst advancing our knowledge into the pathophysiology of these diseases." | ( Marenzana, M; Vande Velde, G, 2015) |
| "Moreover, GW2580 treatment slowed disease progression, attenuated motoneuron cell death and extended survival of SOD1(G93A) mice." | ( Francos-Quijorna, I; Gomez-Nicola, D; López-Vales, R; Mancuso, R; Martínez-Muriana, A; Navarro, X; Olmos-Alonso, A; Osta, R; Perry, VH, 2016) |
| "Systemic PHSCN monotherapy prevented disease progression for up to 14 months in Phase I clinical trial." | ( Livant, DL; Veine, DM; Yao, H, 2016) |
| "Data on CA-125 as a predictor of disease progression (PD) in ovarian cancer come predominantly from patients with platinum-sensitive disease receiving chemotherapy alone." | ( Ayhan, A; Burges, A; Creemers, GJ; Davies, L; Gebski, V; Hilpert, F; Huizing, M; Kristensen, G; Lee, CK; Lindemann, K; Lykka, M; Mirza, MR; Pujade-Lauraine, E; Raspagliesi, F; Romero, I; Rubio, MJ, 2016) |
| "Mechanisms driving disease progression and therapy resistance have not been studied in TCF3-PBX1 BCP-ALL." | ( Burmeister, T; Edgren, H; Eldfors, S; Gökbuget, N; Heckman, CA; Kallioniemi, O; Kontro, M; Kuusanmäki, H; Majumder, MM; Parsons, A; Pemovska, T; Porkka, K; Wennerberg, K, 2017) |
| "Monitoring disease progression and treatment response in young patients is desirable, but serial imaging via CT is often considered prohibitive, and detailed functional information cannot be obtained using conventional imaging techniques." | ( Clancy, JP; Cleveland, ZI; Roach, DJ; Thomen, RP; Walkup, LL; Woods, JC, 2017) |
| "Cumulative incidence of on-treatment disease progression (PD)/death at 4 years was 24% (95% CI, 17-33%); K-M 4-year overall survival was 78% (68-85%)." | ( Brümmendorf, TH; Cortes, JE; Gambacorti-Passerini, C; Kantarjian, HM; Khoury, HJ; Kim, DW; Leip, E; Lipton, JH; Matczak, E; Noonan, K; Schafhausen, P, 2016) |
| "Recently, two therapies that slow disease progression, nintedanib and pirfenidone, have been approved for the treatment of IPF, yet the clinical unmet need is still high for IPF patients given their failure to stop disease progression and their potential side-effect profiles." | ( Clarke, DL; Crestani, B; Murray, LA; Sleeman, MA, 2017) |
| "Without effective treatment, disease progression frequently leads to liver failure and death." | ( Bowlus, CL; Kenney, JT; Navarro, R; Rice, G, 2016) |
| "Unfortunately most patients develop disease progression in less than a year of treatment with crizotinib, the first-generation ALK-inhibitor." | ( Kloecker, G; Perez, CA; Rios-Perez, J; Salame, BK; Srinivasamaharaj, S, 2016) |
| "The aim of our study is to evaluate the disease progression, specifically in terms of cardiopulmonary function, in a group of consecutive patients chronically treated with intravenous iloprost." | ( Amato, G; Bellofiore, S; Benenati, A; Converso, G; Di Gangi, M; Farina, A; Foti, R; Mulè, M; Visalli, E, 2017) |
| "In April 2013, bone disease progression was evident and he received radiant treatment to sacral spine." | ( Ballatore, Z; Battelli, N; Berardi, R; Cascinu, S; De Lisa, M; Pagliacci, A; Pistelli, M, 2016) |
| "Factors associated with reduced risk of disease progression included good performance status (PS), long period between diagnosis and docetaxel treatment, and smoking for <10 pack-years." | ( Daniluk, J; Krawczyk, P; Milanowski, J; Mlak, R; Powrózek, T; Szczyrek, M; Szudy-Szczyrek, A; Wojas-Krawczyk, K; Zwolak, A, 2017) |
| "Imaging markers for monitoring disease progression, recovery, and treatment efficacy are a major unmet need for many neurological diseases, including epilepsy." | ( Gröhn, O; Laitinen, T; Miettinen, T; Salo, RA; Sierra, A, 2017) |
| "Crizotinib beyond disease progression is an option in patients with oligoprogressive disease, especially in presence of isolated central nervous system (CNS) relapse, provided that local ablative therapy (mainly radiotherapy) to the brain is administered." | ( Chiari, R; Crinò, L; Matocci, R; Metro, G; Tazza, M, 2017) |
| "Following disease progression, patients randomly assigned to EGFR-TKI had shorter OS than those randomly assigned to chemotherapy (12." | ( Davies, L; Fukuoka, M; Gebski, V; Gralla, RJ; Inoue, A; Lee, CK; Lord, S; Marschner, I; Mitsudomi, T; Mok, T; Nakagawa, K; Rosell, R; Thongprasert, S; Tu, YK; Wu, YL; Yang, JC; Zhou, C, 2017) |
| "In the multivariate analysis for disease progression, the best response to chemotherapy and AFP decline were independent factors, with p values of 0." | ( Chang, HH; Chen, JS; Chia-Hsun Hsieh, J; Chou, WC; Hou, MM; Huang, CY; Lee, CL; Lin, YC; Teng, W; Tseng, YT; Yang, TS, 2018) |
| "Patients were treated with AA until disease progression, death, or unacceptable toxicity." | ( Bada, M; Bianchi, G; Boccasile, S; Bove, P; Carrieri, G; Castellan, P; Chiodini, P; Cindolo, L; De Nunzio, C; De Tursi, M; Ditonno, P; Giacinti, S; Laudisi, A; Ludovico, GM; Martorana, E; Micali, S; Natoli, C; Rizzo, M; Scarcia, M; Schips, L; Selvaggio, O; Topazio, L; Valeriani, M, 2017) |
| "Vismodegib therapy was continued until disease progression, intolerable toxicity, or withdrawal of consent." | ( Abou-Alfa, GK; Chandra, P; Cheeti, S; Colburn, D; Graham, RA; Lewis, LD; LoRusso, P; Maitland, M; Simmons, B; Williams, S, 2017) |
| "Moreover, empagliflozin slowed kidney disease progression and reduced the need for renal replacement therapy." | ( Martens, P; Mullens, W; Verbrugge, FH, 2017) |
| "Patients with OC who experienced disease progression 6 to 12 months after their last platinum treatment were randomly assigned 1:1 to the experimental sequence of NPBC followed by PBC at subsequent relapse or the standard reverse treatment sequence." | ( Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U, 2017) |
| "The average time cessation of disease progression or new lesion formation after CsA administration was 2." | ( Bach, DQ; Badri, O; Gracey, LE; Ho, AW; Kroshinsky, D; Liu, KJ; Raff, AB; Ratushny, V; Schalock, P; St John, J; Sugai, DY, 2017) |
| "There was no disease progression in either treatment arm at three months' follow-up." | ( Dahm, P; Gudeloglu, A; Jung, JH; Kiziloz, H; Konety, BR; Kuntz, GM; Miller, A, 2017) |
| "The serum SP-D level was a predictor of disease progression and prognosis in patients with IPF treated with pirfenidone." | ( Chiba, H; Hasegawa, Y; Ikeda, K; Kuronuma, K; Nishikiori, H; Otsuka, M; Saito, A; Shiratori, M; Takahashi, H; Yamada, G; Yokoo, K, 2017) |
| "Accelerated disease progression after the discontinuation of nintedanib therapy for IPF." | ( Asakura, T; Betsuyaku, T; Ishii, M; Kamata, H; Masuzawa, K; Okamori, S; Yasuda, H, 2017) |
| "Moreover, disease progression is no longer an absolute contraindication for continuing the regorafenib treatment." | ( Archibugi, L; Botticelli, A; Castaldi, N; Falcone, R; Marchetti, P; Mazzuca, F; Osti, MF; Roberto, M, 2017) |
| "Furthermore, no disease progression occurred in recipient mice treated with tamoxifen after the onset of EAE." | ( Akiba, Y; Kondo, M; Kuwabara, T; Mikami, T; Mukozu, T, 2018) |
| "Early disease progression in the chemotherapy to LR interval occurred in approximately 15% of patients and was associated with extremely poor survival." | ( Carnaghi, C; Cimino, M; Darwish, SS; Del Fabbro, D; Donadon, M; Personeni, N; Procopio, F; Rimassa, L; Santoro, A; Torzilli, G; Vigano, L, 2018) |
| "Of those with disease progression who were offered second-line therapy, 30 received NG, 8 GEM alone, and 22 best supportive care." | ( Kellett, C; Kim, CA; Lambert, P; Zhang, H, 2018) |
| "To evaluate the natural course of disease progression in patients with Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB), identify potential end points for future therapy trials, and characterize biomarkers related to the disease." | ( Alexanderian, D; Cleary, M; Eugen Mengel, K; Harmatz, P; Haslett, P; Nestrasil, I; Shapiro, E; Whiteman, D; Whitley, CB, 2018) |
| "We aimed to compare the disease progression of treated [liver transplantation (LT) or tafamidis] versus untreated patients with hATTR V30M." | ( Castro, J; Conceição, I; de Carvalho, M; Miranda, B, 2018) |
| "The effect of treatment on disease progression was analysed using linear mixed-effects modelling." | ( Castro, J; Conceição, I; de Carvalho, M; Miranda, B, 2018) |
| "Aspirin treatment decreased renal disease progression in a model adjusted for age, baseline kidney function, and diabetes mellitus (HR, 0." | ( Abad, S; Arroyo, D; Bernis, C; de Sequera, P; de Vinuesa, SG; Delgado, R; Fernández-Juárez, G; Goicoechea, M; Luño, J; Morales, E; Ortiz, A; Quiroga, B; Torres, A; Verdalles, U; Verde, E, 2018) |
| "Overall, worsening and disease progression as measured by the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog), Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) and Clinical Dementia Rating (CDR) did not correlate with the duration of AChE-I treatment." | ( Bauer, C; Frölich, L; Heuser, I; Joachim, LK; Kornhuber, J; Maier, W; Peters, O; Rüther, E; Wiltfang, J, 2018) |
| "Treatment was continued until disease progression, patient withdrawal, or unacceptable toxic effects." | ( Feng, YL; Huang, HQ; Huang, X; Lan, CY; Li, JD; Li, YF; Liu, Q; Shen, JX; Wang, Y; Xiong, Y; Zhang, YN; Zheng, M, 2018) |
| "Patients who experienced disease progression treated with dabrafenib monotherapy or in combination with trametinib as second line or later in an open-label, non-randomised, phase II study." | ( Li, J; Redhu, S; Ricculli, ML; Sasane, M; Signorovitch, J; Yao, Z; Zhang, J; Zhao, J, 2018) |
| "The patient died of disease progression one month after discontinuing osimertinib treatment." | ( Hirashima, T; Masuhiro, K; Morishita, N; Morita, S; Nasu, S; Okamoto, N; Shiroyama, T; Suzuki, H; Takada, H; Takata, S; Tanaka, A, 2018) |
| "Most patients had disease progression as the best response to treatment (75." | ( Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC, 2019) |
| "In prostate cancer, disease progression after primary treatment and subsequent androgen deprivation therapy is common." | ( Baumann, M; Hölscher, T; Kotzerke, J; Krause, M; Löck, S; Lohaus, F; Troost, EGC; Wirth, M; Zöphel, K, 2019) |
| "Treatment beyond disease progression was allowed if the investigator judged ongoing clinical benefit." | ( Boyer, MJ; Cheema, PK; Dechaphunkul, A; Gray, JE; Lee, JS; McKeown, A; Ohe, Y; Planchard, D; Ramalingam, SS; Rukazenkov, Y; Takahashi, T; Tiseo, M; Todd, A, 2019) |
| "To assess the patterns of disease progression in advanced/metastatic epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) on first-line treatment with erlotinib and identify potential prognostic factors for progression-free survival (PFS)." | ( Aguiar-Bujanda, D; Artal-Cortes, Á; DE Castro, J; Fírvida, JL; Fuentes, JC; Galán, R; Gordo, R; Oramas, J; Ortega-Granados, AL; Trigo, J, 2019) |
| "After further disease progression, 8 cycles of paclitaxel were administered." | ( Collins, N; Elisofon, SA; Fawaz, R; Lee, CK; Ocwieja, KE; Sharma, TS; Shulman, DS; Vakili, K; Vargas, SO, 2019) |
| "Treatment continued until disease progression, development of unacceptable toxic effects, or withdrawal of consent." | ( Aghajanian, C; Brose, MS; Cohn, AL; Di Simone, C; Dutcus, CE; Guo, M; Hyman, DM; Makker, V; Mier, J; Rasco, D; Sachdev, P; Schmidt, EV; Shumaker, R; Stepan, DE; Taylor, M; Vogelzang, NJ, 2019) |
| "The effect of varying disease progression rates was explored by comparing profiles on- and off-treatment." | ( Adalig, B; Chavan, C; D'Agate, S; Della Pasqua, O; Manyak, M; Oelke, M; Palacios-Moreno, JM; Roehrborn, C; Wilson, T, 2020) |
| "Therapeutic vaccines to prevent Chagas disease progression to cardiomyopathy are under development because the only available medications (benznidazole and nifurtimox) are limited by their efficacy, long treatment course, and side effects." | ( Asti, L; Bartsch, SM; Bottazzi, ME; Falcón-Lezama, JA; Hotez, PJ; Lee, BY; Meymandi, S; Randall, S; Strych, U, 2019) |
| "Targeted treatments to prevent disease progression and to preclude malignancy are not yet available." | ( Carey, EJ; Yokoda, RT, 2019) |
| "Two patients died due to rapid disease progression before treatment." | ( Bo, J; Sun, L; Wang, Q; Yuan, L; Zhao, Y, 2019) |
| "Seven LR patients had disease progression; all were successfully treated with chemotherapy." | ( Depani, S; Krailo, M; Nicholson, J; Stoneham, S; Xia, C, 2019) |
| "Uncertainty on how to treat patients at disease progression prompted us to develop a consensus document on post-immunotherapy options in Spain for patients with advanced wild-type lung adenocarcinoma." | ( de Castro, J; Felip, E; García-Campelo, R; Garrido, P; Isla, D; Lianes, P; Paz-Ares, L; Trigo, JM, 2020) |
| "Markers of worse prognosis and disease progression are well established and include recurrence of HF decompensation, intolerance to the neurohormonal standard pharmacological treatment, and resistance to loop diuretics." | ( Ambrosio, G; Grassi, G; Gronda, E; Napoli, C; Sacchi, S; Vanoli, E, 2020) |
| "In this study we characterized disease progression over 48 weeks among boys receiving deflazacort vs prednisone/prednisolone placebo arm treatment in two recent Duchenne muscular dystrophy (DMD) clinical trials." | ( Cox, DA; Darras, BT; Elfring, G; Landry, J; McDonald, CM; McDonnell, E; Peltz, SW; Sajeev, G; Shieh, PB; Signorovitch, J; Souza, M; Yao, Z, 2020) |
| "9 of the patients who developed disease progression during crizotinib treatment had new brain metastases or increased preexisting cranial foci." | ( Deng, H; Ding, C; Li, B; Li, L; Liu, Y; Lv, T; Peng, J, 2019) |
| "Association with disease progression while receiving abiraterone/enzalutamide therapy was apparent in this study; however, further studies are needed to elaborate the therapeutic and prognostic implications." | ( Barata, PC; Chapman, L; Christensen, BR; Cotogno, P; Layton, JL; Ledet, EM; Lewis, BE; Manogue, C; Moses, M; Ranasinghe, L; Sartor, O; Steinwald, P, 2020) |
| "In June 2015, a CT scan revealed disease progression and first-line epirubicin/ifosfamide treatment was started, followed by epirubicin in monotherapy." | ( Bloise, F; Falcone, A; Galli, L; Manacorda, S; Nuzzo, A; Paolieri, F; Sammarco, E; Sbrana, A, 2020) |
| "Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy." | ( Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D, 2020) |
| "Pulmonary sarcoidosis patients who get disease progression despite corticosteroid treatment or can't tolerate corticosteroid required second-line drug." | ( Fang, C; Jing, X; Wang, N; Xu, Z; Zhang, Q, 2019) |
| "26 functional status assessments (7 in disease progression/after treatment intensification) in both scales were analyzed in 19 patients with PAH confirmed in RHC." | ( Brzezińska-Rajszys, G; Jagiełłowicz-Kowalska, D; Migdał, A; Powichrowska, Z; Żuk, M, 2020) |
| "Based on distinct patterns of disease progression exclusively observed in the nivolumab-treated cohort, but not in the regorafenib- or BSC/placebo-treated cohorts, 4-fold increases in TGK and TGR ratios as well as a 40% increase in TGR were the cut-off values used to define HPD; 12." | ( Choi, HJ; Choi, SJ; Chon, HJ; Chung, HC; Kang, B; Kim, C; Kim, CG; Kim, DJ; Kim, HR; Kim, KH; Kim, YY; Lim, HY; Park, SH; Shin, EC; Yoon, SE, 2021) |
| "At the time of disease progression, FOLFIRI cetuximab regimen was reintroduced resulting in stabilization of disease and he continued with capecitabine cetuximab therapy until disease progression in October 2016." | ( Antonuzzo, L; Castiglione, F; Di Costanzo, F; Lastraioli, E; Lavacchi, D; Messerini, L; Palmieri, VE, 2020) |
| "We developed a disease progression model to characterize the observed variability in lung function decline, measured as percent predicted forced vital capacity (%p-FVC), and its decrease in decline after treatment." | ( Bi, Y; Chen, J; Chowdhury, BA; Karimi-Shah, BA; Marathe, A; Paterniti, MO; Rekić, D; Wang, Y, 2021) |
| "Overall survival and time to disease progression were based on all randomized patients (157 patients); TOX was based on all randomized and treated patients (150 patients)." | ( Chen, RC; Choueiri, TK; Falchook, AD; Feldman, DR; Feuilly, M; George, DJ; Lister, J; Marteau, F; Meng, J; Morris, MJ, 2020) |
| "Comparing kidney disease progression among patients treated with direct oral anticoagulants (DOACs) versus warfarin has not been well studied." | ( Herzog, CA; Reyes, JL; Roetker, NS; Weinhandl, E; Wetmore, JB; Yan, H, 2021) |
| "Nivolumab-treated patients without disease progression at 2 and 3 years had an 82." | ( Antonia, S; Arrieta, O; Barlesi, F; Borghaei, H; Brahmer, J; Burgio, MA; Butts, C; Chiari, R; Chow, LQM; Coudert, B; Crino, L; Czyzewicz, G; de Castro Carpeno, J; Domine, M; Eberhardt, WEE; Felip, E; Frontera, OA; Garassino, MC; García, MA; Gerber, DE; Gettinger, S; Li, A; Marimuthu, S; Pluzanski, A; Ready, N; Spigel, DR; Vokes, EE; Waterhouse, D; Wohlleber, M; Wójcik-Tomaszewska, J, 2021) |
| "From the group with therapy change, 'disease progression' was reason of change in 124 (58." | ( Ferracini, AC; Juliato, CRT; Mazzola, PG; Medeiros, LM; Souza, CM; Stahlschmidt, R, 2021) |
| "The benefit of selexipag treatment on disease progression was more pronounced in patients treated earlier than in patients treated later." | ( Channick, RN; Chin, KM; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, I; McLaughlin, VV; Preiss, R; Rubin, LJ; Sauter, R; Simonneau, G; Sitbon, O; Tapson, V, 2021) |
| "We determined lung function, disease progression and mortality outcomes following initiation of antifibrotic therapy in patients with advanced IPF at the time of treatment initiation compared to those with mild-moderate IPF." | ( Bendstrup, E; Carlson, L; Durheim, MT; Hyldgaard, C; Kalafatis, D; Myllärniemi, M; Sjåheim, T; Sköld, CM; Sutinen, EM, 2021) |
| "In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α-synucleinopathy patients with isolated RBD might develop." | ( Adler, CH; Antelmi, E; Arnaldi, D; Baldelli, L; Boeve, BF; Cesari, M; Dall'Antonia, I; Diederich, NJ; Doppler, K; Dušek, P; Ehgoetz Martens, KA; Ferri, R; Gagnon, JF; Gan-Or, Z; Hermann, W; Högl, B; Hu, MT; Iranzo, A; Janzen, A; Kuzkina, A; Lee, JY; Leenders, KL; Lewis, SJG; Liguori, C; Liu, J; Lo, C; Miglis, MG; Nepozitek, J; Oertel, WH; Plazzi, G; Provini, F; Puligheddu, M; Rolinski, M; Rusz, J; Stefani, A; Summers, RLS; Yoo, D; Zitser, J, 2021) |
| "Primary endpoint was disease progression, a composite of 14-day all-cause death, need for mechanical ventilation, or immunomodulatory therapy." | ( Gaspar, Z; Kiss-Dala, N; Lakatos, B; Lenart, KS; Petrik, B; Szabo, BG; Szlavik, J; Valyi-Nagy, I, 2021) |
| "Among COVID-19 patients at high risk of disease progression, early treatment with oral favipiravir did not prevent their disease progression from nonhypoxia to hypoxia." | ( Abdul Wahab, S; Adnan, NA; Cheng, JT; Chidambaram, SK; Chow, TS; Chuah, CH; Hor, CP; Ker, HB; Lee, HG; Lee, KS; Mustafa, M; Ng, TK; Nordin, N; Ong, SM; Tee, TY; Zaid, M; Zaidan, NZ, 2022) |
| "Finally, NFATc1-induced disease progression towards NASH can be blocked by TUDCA administration." | ( Bogeski, I; Bohnenberger, H; Bremer, SC; Butt, UJ; Ellenrieder, V; Gibhardt, CS; Hessmann, E; Latif, MU; Mercan, S; Moeed, A; Neesse, A; Rahman, R; Rehman, A; Reutlinger, K; Schmidt, GE; Singh, SK; Stejerean-Todoran, I; Stroebel, P, 2022) |
| "In the absence of disease progression, participants will receive pembrolizumab plus olaparib placebo (Group A), pembrolizumab plus olaparib (Group B), or durvalumab monotherapy (Group C)." | ( Bhosle, J; Bria, E; Cho, BC; Gainor, JF; Jabbour, SK; Kato, T; Kim, SJ; Morgensztern, D; Reck, M; Reguart, N; Shentu, Y; Souza, F; Wang, L, 2022) |
| "Following disease progression on olaparib, efficacy of subsequent chemotherapy remains unknown." | ( Aryal, N; Asher, R; Berton, D; Colombo, N; Freimund, AE; Frenel, JS; Huzarski, T; Kim, JW; Korach, J; Ledermann, JA; Lee, CK; Oza, AM; Park-Simon, TW; Pautier, P; Penson, RT; Pignata, S; Pujade-Lauraine, E; Sonke, GS; Tamura, K; Vidal, L, 2022) |
| "Despite having many markers for HIV disease progression, the reliability of these markers remains debatable and most of these cannot be used as valid markers for treatment response." | ( Fortuin, R; Sitole, L; Tugizimana, F, 2022) |
| "Among patients with CLL disease progression on ibrutinib, OS was significantly longer when next-line treatment was chimeric antigen receptor T-cell therapy (median not reached) or venetoclax-based treatment (median 29." | ( Ailawadhi, S; Braggio, E; Call, TG; Chanan-Khan, AA; Ding, W; Hampel, PJ; Hanson, CA; Kay, NE; Kenderian, SS; Koehler, AB; Leis, JF; Muchtar, E; Parikh, SA; Parrondo, R; Rabe, KG; Schwager, SM; Sher, T; Shi, M; Slager, SL; Van Dyke, DL; Wang, Y, 2022) |
| "Patients continued chemotherapy until disease progression or the development of unacceptable toxic effects." | ( Bhosale, P; Chisholm, GB; Flores-Legarreta, A; Frumovitz, M; Gonzales, NR; Hillman, RT; Jhingran, A; Ramalingam, P; Salvo, G, 2023) |
| "Patients continued chemotherapy until disease progression or the development of unacceptable toxic effects." | ( Bhosale, P; Chisholm, GB; Flores-Legarreta, A; Frumovitz, M; Gonzales, NR; Hillman, RT; Jhingran, A; Ramalingam, P; Salvo, G, 2023) |
| "Characterize and compare disease progression by steroid treatment (prednisone, deflazacort, or no steroids) among non-ambulatory boys with DMD." | ( Frean, M; Freimark, J; Goemans, N; Henricson, EK; Hor, KN; Koladicz, K; Lane, H; Marden, JR; Mayer, OH; McDonald, CM; Miller, D; Signorovitch, J; Trifillis, P; Zhang, A, 2023) |
| "Clinical features, disease progression, response to therapy and possible factors predisposing to TKIs response-resistance in meta-MTCs were investigated." | ( Alevizaki, M; Karapanou, O; Paschou, SA; Saltiki, K; Simeakis, G, 2023) |
| "However, optimal treatment for disease progression during MTA therapy remains undetermined." | ( Kato, S; Mibu, A; Nakano, S; Sano, M; Suzuki, Y; Tanimura, K; Yamaguchi, S, 2023) |
| "Based on the risk stratification for disease progression, conservative nonimmunosuppressive and immunosuppressive therapy strategies have been recommended." | ( Bao, K; Li, P; Wang, D; Wang, L; Zhang, M; Zhang, Q, 2023) |
| "Treatment continued until disease progression or other discontinuation criteria were met." | ( Chang, GC; Chen, WC; Chiu, CH; Crawford, N; Hong, Y; Hsia, TC; Hsu, C; Lee, KY; McGill, J; Saintilien, C; Shiah, HS; Su, WC; Takayama, G; Terakawa, H; Uno, M; Yang, JC, 2023) |
| "Patients with disease progression during fulvestrant monotherapy who subsequently received fulvestrant plus palbociclib were assigned to group B." | ( Ishiguro, H; Iwakuma, N; Iwamoto, T; Kikawa, Y; Kobayashi, K; Masuda, N; Niikura, N; Oba, M; Okuno, T; Ozaki, S; Saji, S; Tada, H; Takeshita, T; Toh, U; Tsuneizumi, M; Watanabe, K; Yamamoto, Y, 2023) |
| "We analyzed the disease progression during osimertinib treatment to identify potential treatment strategies." | ( Han, JY; Kim, HS; Kim, HY; Lee, SH; Lee, Y; Lim, KY, 2023) |
| "ctDNA analysis can be used to monitor disease progression and provide more personalized treatment." | ( Bauer, S; Bialick, S; George, S; Gómez-Peregrina, D; Grassian, A; Heinrich, MC; Jones, RL; Kang, YK; Mir, O; Newberry, K; Pantaleo, MA; Rutkowski, P; Schöffski, P; Serrano, C; Shi, H; Tap, WD; Trent, JC; von Mehren, M, 2023) |
| "Study treatment will be continued until disease progression according to RECIST 1." | ( Berres, ML; Gonzalez-Carmona, M; Kehmann, L; Keitel, V; Luedde, T; Modest, DP; Mohr, R; Roderburg, C; Strassburg, C; Trautwein, C; Venerito, M; Wree, A, 2023) |
| "Six patients exhibited disease progression on imaging without PSA elevation during HSPC treatment, three during first-line castration-resistant PC (CRPC) treatment, and two during late-line CRPC treatment." | ( Bando, Y; Fujisawa, M; Furukawa, J; Hara, T; Harada, K; Nakano, Y; Okamura, Y; Terakawa, T, 2023) |
| "Some patients may have disease progression and may need treatment with an anti-COVID-19 agent, hospitalization, and even intensive care." | ( Chen, Y; Chiu, TY; Ha, SC; Koh, CC; Tsai, HW; Weng, CC, 2023) |
| "Three patients had disease progression during follow-up after therapy had been discontinued; none have died." | ( Agarwalla, PK; Barker, FG; Bota, DA; Brastianos, PK; Brown, PD; Cahill, DP; Campian, J; Cohen, AL; Curry, WT; De La Fuente, MI; Galanis, E; Gerstner, ER; Geyer, S; Iafrate, AJ; Kabat, B; Kaufmann, TJ; Knopp, M; Kumthekar, P; Lesser, GJ; Mann, B; Reardon, DA; Ruff, MW; Santagata, S; Shih, HA; Tabrizi, S; Thierauf, J; Twohy, E; Vora, S, 2023) |
| "In BR/UR-LA pancreatic cancer without disease progression after GnP, multimodal treatment including CRT, conversion surgery and the scheduled postoperative chemotherapy may be effective." | ( Jingu, K; Kishida, K; Mizuma, M; Nakagawa, K; Omata, S; Suzuki, Y; Takahashi, N; Umezawa, R; Unno, M; Yamamoto, T, 2023) |
| "Eligible patients had disease progression on at least one previous line of systemic therapy and no alternative standard therapy available to them, and an Eastern Cooperative Oncology Group performance status of 0-1 (or equivalent for adolescents aged 12-17 years)." | ( Arnold, D; Carranza, O; Crow, L; Doi, T; Gutierrez, M; Hammond, C; Iyer, G; Loriot, Y; Lugowska, I; Massard, C; Minchom, A; Najmi, S; Pant, S; Qin, S; Reardon, DA; Santiago-Walker, A; Schuler, M; Stuyckens, K; Sweiti, H; Tabernero, J; Thomas, S; Triantos, S; Winter, H; Witt, O, 2023) |
| "Monitoring disease progression is particularly important for determining the optimal treatment strategy in patients with liver disease." | ( Bade, R; Kaiser, N; Planert, M; Plath, J; Río Bártulos, C; Schumacher, M; Senk, K; Stroszczynski, C; Wiggermann, P; Woetzel, J, 2023) |